Related Experiment Video
Updated: Oct 4, 2025

An Alternative Culture Method to Maintain Genomic Hypomethylation of Mouse Embryonic Stem Cells Using MEK Inhibitor PD0325901 and Vitamin C
Published on: June 1, 2018
DNA-methylation dynamics across short-term, exposure-containing CBT in patients with panic disorder
Sylvain Moser1,2, Jade Martins3, Darina Czamara3
1Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany. sylvain_moser@psych.mpg.de.
Abstract:
Interaction of genetic predispositions and environmental factors via epigenetic mechanisms have been hypothesized to play a central role in Panic Disorder (PD) aetiology and therapy. Cognitive Behavioral Therapy (CBT), including exposure interventions, belong to the most efficient treatments of PD although its biological mechanism of action remains unknown. For the first time, we explored the dynamics and magnitude of DNA-methylation and immune cell-type composition during CBT (n = 38) and the therapeutic exposure intervention (n = 21) to unravel their biological correlates and identify possible biomarkers of therapy success. We report transient regulation of the CD4 + T-Cells, Natural Killers cells, Granulocytes during exposure and a significant change in the proportions of CD4 + T cells, CD8 + T cells and B-Cells and Granulocytes during therapy. In an epigenome-wide association study we identified cg01586609 located in a CpG island and annotated to the serotonin receptor 3 A (HTR3A) to be differentially methylated during fear exposure and regulated at gene expression level with significant differences between remitters and non-remitters (p = 0.028). We moreover report cg01699630 annotated to ARG1 to undergo long lasting methylation changes during therapy (paired t test, genome-wide adj.p value = 0.02). This study reports the first data-driven biological candidates for epigenetically mediated effects of acute fear exposure and CBT in PD patients. Our results provide evidence of changes in the serotonin receptor 3 A methylation and expression during fear exposure associated with different long-term CBT trajectories and outcome, making it a possible candidate in the search of markers for therapy success. Finally, our results add to a growing body of evidence showing immune system changes associated with PD.
Insights
This study reveals epigenetic changes in panic disorder (PD) patients undergoing cognitive behavioral therapy (CBT). DNA methylation of the serotonin receptor 3A (HTR3A) and immune cell shifts are linked to therapy outcomes, offering potential biomarkers for treatment success.
Area of Science:
- Neuroscience
- Psychiatry
- Immunology
Background:
- Panic Disorder (PD) etiology is linked to genetic and environmental factors interacting via epigenetic mechanisms.
- Cognitive Behavioral Therapy (CBT) is effective for PD, but its biological underpinnings are unclear.
- Understanding epigenetic and immune correlates of CBT is crucial for identifying therapy biomarkers.
Purpose of the Study:
- To investigate DNA methylation and immune cell composition changes during CBT and exposure therapy in PD patients.
- To identify potential epigenetic and immune biomarkers associated with CBT treatment success.
- To elucidate the biological mechanisms of action for CBT in Panic Disorder.
Main Methods:
- Epigenome-wide association study (EWAS) analyzing DNA methylation.
- Flow cytometry to assess immune cell-type composition.
- Longitudinal study design tracking changes during CBT and exposure interventions.
Main Results:
- Transient regulation of CD4+ T-Cells, Natural Killer cells, and Granulocytes during exposure.
- Significant shifts in CD4+ T cells, CD8+ T cells, B-Cells, and Granulocytes proportions during therapy.
- Differential methylation of HTR3A (cg01586609) during fear exposure, linked to treatment outcomes.
- Long-lasting methylation changes in ARG1 (cg01699630) during therapy.
Conclusions:
- First data-driven biological candidates for epigenetically mediated effects of fear exposure and CBT in PD.
- HTR3A methylation and expression changes during fear exposure are associated with CBT trajectories and outcomes.
- Findings suggest HTR3A as a potential biomarker for therapy success in PD.
- Results support the role of immune system alterations in PD and response to treatment.
More Related Videos
Related Concept Videos
Panic Disorder
Behavior Therapy
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
Cognitive Therapy

